Evidence map›Paper›PMID 30064664›Full record

ReviewTrends in cancer2018

Seeking Convergence and Cure with New Myeloma Therapies.

Priya Choudhry, Derek Galligan, Arun P Wiita

Abstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Trends in cancer, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
  2. Article
  3. Article
  4. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors.

Priya ChoudhryDepartment of Laboratory Medicine, University of California, San Francisco, CA, USA; Helen Diller Family Comprehensive Cancer Center, University of California, San Francisco, CA, USA; These authors contributed equally.
Derek GalliganDepartment of Medicine, University of California, San Francisco, CA, USA; Helen Diller Family Comprehensive Cancer Center, University of California, San Francisco, CA, USA; These authors contributed equally.
Arun P WiitaDepartment of Laboratory Medicine, University of California, San Francisco, CA, USA; Helen Diller Family Comprehensive Cancer Center, University of California, San Francisco, CA, USA. Electronic address: arun.wiita@ucsf.edu.

Funding

In vivo monitoring of oxidative protein folding through time-resolved quantitative mass spectrometryDP2GM123500 · NIGMS · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI WIITA, ARUN P. · 2016 to 2016
$1.9M
Global Assessment of Myeloma Response to ChemotherapyK08CA184116 · NCI · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI WIITA, ARUN P. · 2014 to 2018
$684k
NCI NIH HHS K08 CA184116NIGMS NIH HHS DP2 GM123500
6 · The paper itself

Abstract

For over a decade, the mainstay of multiple myeloma therapy has been small molecules that directly attack malignant plasma cell biology. However, potent immunotherapies have recently emerged, transforming the myeloma therapeutic landscape. Here we first review new promising strategies to target plasma cells through protein homeostasis and epigenetic modulators. We then discuss emerging immunotherapy strategies that are leading to dramatic results in patients. Finally, we focus on recent preclinical data suggesting that enforcing cell-surface antigen expression through small molecules may enhance immunotherapy efficacy and avoid resistance. We argue that these emerging observations point the way toward potential convergence between drug classes. With recent rapid progress we may finally be on the verge of the 'C' word: a cure for myeloma.

Indexed as

Antibodies, MonoclonalAntigens, NeoplasmAntigens, SurfaceAntineoplastic AgentsEpigenesis, GeneticHumansImmunotherapyMolecular Targeted TherapyMultiple MyelomaProteasome InhibitorsSmall Molecule LibrariesAntibodies, MonoclonalAntigens, NeoplasmAntigens, SurfaceAntineoplastic AgentsdaratumumabProteasome InhibitorsSmall Molecule LibrariesCAR-Tcell surfaceepigeneticsimmunotherapymyelomaprotein homeostasis

Identifiers

PMID30064664
PMCPMC6083854

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.